Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
Wolfgang Miesbach; Linus Völker/LinkedIn
Dec 17, 2025, 06:28

Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Caplacizumab as Frontline Therapy for iTTP: Is Plasmapheresis Still Needed? Priv.-Doz. Dr.med. Linus Völker presented at ASH compelling evidence that caplacizumab can work without plasma exchange in selected patients.

Systematic evidence: >100 plasma-free iTTP episodes
· First case reports and small series: ~10 episodes
· Kühne et al., Blood 2024 (Austria/Germany): 42 episodes with 90.5% clinical response without TPE and a median time to platelet normalization: 3 days (vs. 4 days with TPE, p=0.31), however, 4 patients required rescue TPE
· Knöbl, ISTH 2025: 34 episodes
· MAYARI Trial, ISTH 2025: 46 episodes and 93.5% remission without TPE (43/46 patients), 95.7% remission overall (44/46 patients)

This strategy is off-label and requires institutional capabilities:
✓ Extensive iTTP treatment experience at specialized centers
✓ 24/7 ADAMTS13 activity measurement (turnaround in hours, not days)
✓ Immediate caplacizumab access via emergency pharmacy
✓ Plasma exchange instantly available (safety net, not routine)
✓ No contraindications to caplacizumab therapy

Crucial to identify the right patient
There are clinical characteristics favoring a plasma-free approach
· Immediate platelet recovery after the first caplacizumab dose
· Clinically stable condition at presentation
· Lower LDH levels at onset
· Less severe organ involvement (lower ICU admission rates)

A fascinating glimpse into how frontline caplacizumab, in the right setting with the right patient, may allow truly plasma-free management for selected iTTP cases.”

Wolfgang Miesbach on Linus Völker's Presentation of Caplacizumab as Frontline Therapy for iTTP

All from ASH25 featured in Hemostasis Today.

ASH2025 ASH25 bleeding disorders Blood Journals Portfolio Caplacizumab Health Hematology Hemostasis Hemostasis Today iTTP Medicine TPE Wolfgang Miesbach
NewsFeed